Europe Market Report for Bone Morphogenic Protein Growth Factor Therapy 2017 – MedCore

Europe Market Report for Bone Morphogenic Protein Growth Factor Therapy 2017 – MedCore

0

Bone morphogenetic proteins (BMPs) are growth factors that induce the formation of bone after a fracture. In nature, these proteins have a critical role during embryonic development in the formation of the skeleton. There are twenty different BMPs that have been discovered thus far, of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for use in specific orthopedic procedures. The commercial versions of these products are produced by recombinant genetic engineering, which results in a recombinant human protein. The recombinant human BMP-2 (rhBMP-2) is marketed as a commercial product by Medtronic, Inc. and is called Infuse® (InductOS® in Europe), while BMP-7 has been commercialized by Stryker Inc. and is sold to Olympus under the name of OP-1®. Both molecules mediate the process of osteoblast differentiation. BMP-2 is capable of stimulating immature mesenchymal cells to form into bone, while BMP-7 has been shown to be capable of stimulating cartilage growth.

  • Year: 2017
  • Scope: 2013-2023
  • Region: Europe
  • Published Date: 6/1/2017
  • Pages: 465
  • Type: MedCore

General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
This market went through a decline a result of Olympus exiting the market with its OP-1® BMP-7 product. However, the market has stabilized and is expected to a growth over the forecast period. Despite the recently acquired approval for Infuse® to be used as an adjunct in all spinal interbody fusion procedures, the level of absorption will remain limited due to the two products’ substantially different indications. As such, unless InductOS® can build upon its indications, the market is expected to grow at a slower rate over the forecast period.
In addition to the market value, the contracting ASP was also a result of the discontinuation of OP-1®, which was sold at a premium compared to InductOS®. Prices will remain stable throughout the remainder of the forecast period as Medtronic has no immediate plans to change its pricing scheme for the product. Furthermore, with the newly monopolized market, it is expected that demand for the product will remain fairly inelastic to any changes in price.
The countries with the largest BMP market in 2016 were France and Germany, with France being the leader. The negotiated reimbursement in France has allowed it to secure a large share of the overall European market. Germany, the largest country by population, was the second largest consumer; penetrating the German market remains difficult as Medtronic is tasked with proactively negotiating the reimbursement rates with various health insurers. Meanwhile, Austria and Portugal remained the smallest of the markets.



The "Europe Market Report Suite for Orthopedic Biomaterials 2017 - MedSuite" includes analysis on the following companies currently active in this market:
Fidia
Medtronic
TRB Chemedica
Meda Pharma
Sanofi Genzyme
Depuy Synthes
Bioventus
Laboratoire Genevrier
Recordati
Stryker
RTI Biologics
Croma-Pharma
Zimmer Biomet
Others include: Anika Therapeutics, Bioiberica, Documedica, Ferring, Geistlich, Integra Biologics, Kuros, LCA Pharma, Orotech, Plasmaconcept AG, Stella PharmaceuticalsAlphatec Spine, etc
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.




Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Not Exactly What You Need?
close-link
close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link
close-link